New Dual-Targeting antibody enters human trials for Hard-to-Treat cancers
NCT ID NCT07582822
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The main goals are to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JH021 (a bispecific antibody targeting EGFR and cMET proteins)
What this could lead to
If successful, this could lead to a new treatment option for advanced solid tumors, especially for lung cancer patients who have stopped responding to current therapies.
What could go wrong
This is an early Phase 1 trial with only 60 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital
Zhengzhou, Henan, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hunan Cancer Hospital
Changsha, Hunan, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nanjing Tianyinshan Hospital
Nanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Shanghai East Hospital
Shanghai, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai Pulmonary Hospital Affiliated to Tongji University
Shanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Shanxi Cancer Hospital
Taiyuan, Shanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yibin Second People's Hospital
Yibin, Sichuan, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact